# US 2011/0300629 A1 · TRAIL trimers, methods and uses therefor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2011/0300629 A1
- Document ID: US20110300629A1
- Status: Published application
- Kind: A1
- Application number: 13/155,577
- Filed: 2011-06-08
- Published: 2011-12-08
- Earliest claimed: 2010-06-08
- Assignees: Washington University
- Inventors: William G. Hawkins; Dirk Spitzer; Richard S. Hotchkiss
- Web page: https://patentgrep.com/patent/US20110300629A1

## CPC

- C07K 14/4747: {Apoptosis related proteins}
- C07K 14/52: Cytokines; Lymphokines; Interferons
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Disclosed are TNF-related apoptosis-inducing ligand (TRAIL) trimers (TR3) and nucleic acids encoding covalently linked TRAIL trimers. A TRAIL trimer can have greater stability compared to native TRAIL, and can retain the native killing ability of TRAIL. Target specificity of a TR3 can be shown by blocking its activity with soluble death receptor 5 (DR5-Fc). Also disclosed are modified TRAIL trimers and nucleic acids encoding them. These modifications include additional functional domains, such as antibody fragments (scFvs). A TR3 comprising an additional functional domain can allow for cell-specific delivery of the TR3. In some configurations, a modification such as the addition of a functional domain can be stoichiometrically controlled. In some configurations, a modification can be inconsequential with regard to the bioactivity of TRAIL. In various embodiments, a TR3, including a modified TR3, can be a cancer-selective drug. In some configurations, a TR3 that comprises an additional biologically active moiety such as a functional domain of a protein can have fewer off-target toxicities compared to TRAIL alone. In some configurations, a TR3 that comprises an additional biologically active moiety such as a functional domain of a protein can have enhanced killing capacities compared to the moiety alone. In some aspects, TR3 activity can be targeted to an RBC membrane. The inventors disclose TR3-decorated RBCs that target cell killing in a model of pancreatic cancer.

## Claims

### Claim 1

A trimer of a TNF-related apoptosis-inducing ligand (TRAIL), comprising three consecutive extracellular TRAIL domains fused together in a head-to-tail configuration.

### Claim 2 (depends on 1)

A trifler in accordance with claim 1, wherein each TRAIL domain comprises a sequence having at least 99% identity with SEQ ID NO: 1.

### Claim 3 (depends on 1)

A trimer in accordance with claim 1, further comprising a cell-targeting domain.

### Claim 4 (depends on 2)

A trimer in accordance with claim 2, wherein the cell targeting domain is an antibody fragment.

### Claim 5 (depends on 3)

A trimer in accordance with claim 3, wherein the antibody fragment is an scFv.

### Claim 6 (depends on 1)

A trimer in accordance with claim 1, further comprising a spacer between the cell-targeting domain and the TRAIL domains.

### Claim 7 (depends on 6)

A trimer in accordance with claim 6, wherein the spacer comprises a plurality of short consensus repeats (SCRs).

### Claim 8 (depends on 6)

A trimer in accordance with claim 6, wherein the spacer comprises 4 short consensus repeats.

### Claim 9 (depends on 6)

A trimer in accordance with claim 6, wherein the spacer comprises globular domains of human complement regulatory proteins decay accelerating factor (DAF, CD55) and complement receptor 1 (CR1, CD35).

### Claim 10 (depends on 6)

A trimer in accordance with claim 6, wherein the spacer comprises four SCRs and globular domains of the human complement regulatory proteins decay accelerating factor (DAF, CD55) and complement receptor 1 (CR1, CD35).

### Claim 11 (depends on 1)

An anticancer therapeutic comprising a trimer of claim 1.

### Claim 12 (depends on 1)

A nucleic acid comprising a sequence encoding the trimer of claim 1.

### Claim 13 (depends on 12)

A vector comprising the nucleic acid of claim 12.

### Claim 14 (depends on 13)

The vector of claim 13, further comprising a sequence encoding a signal peptide.

### Claim 15 (depends on 13)

The vector of claim 13, wherein said vector is a plasmid.

### Claim 16

A method of inducing apoptosis in a tumor cell, comprising contacting the cell with a trimer of a TNF-related apoptosis-inducing ligand (TRAIL), comprising three consecutive extracellular TRAIL domains fused together in a head-to-tail configuration.

### Claim 17 (depends on 16)

A method of inducing apoptosis in a tumor cell in accordance with claim 16, wherein the trimer further comprises a cell-targeting domain.

### Claim 18 (depends on 17)

A method of inducing apoptosis in a tumor cell in accordance with claim 17, wherein the cell-targeting domain is an scFv.

### Claim 19 (depends on 17)

A method of inducing apoptosis in a tumor cell in accordance with claim 17, wherein the trimer further comprises spacer comprising four SCRs, and globular domains of the human complement regulatory proteins decay accelerating factor (DAF, CD55) and complement receptor 1 (CR1, CD35).

### Claim 20 (depends on 16)

A method of inducing apoptosis in a tumor cell in accordance with claim 16, wherein the tumor cell is a pancreatic cancer cell.
